- Petwealth has launched publicly with $1.7 million in funding to develop an at‑home diagnostics platform for pets.
- The company offers PCR‑based diagnostic kits designed to detect health markers in dogs and cats.
- The flagship Petwealth Pack combines fecal, oral, and respiratory PCR panels in a single at‑home testing kit.
- Results are delivered within 24 to 48 hours alongside AI‑generated health insights.
- Petwealth also announced partnerships with Kennel Connection and Pawp to expand diagnostic access and veterinary telehealth support.
Petwealth announced its public launch alongside $1.7 million in funding and new partnerships aimed at expanding access to at‑home diagnostic testing for companion animals.
The Miami‑based company is developing a platform that combines PCR‑based diagnostic testing with artificial intelligence to generate health insights for pet owners, veterinarians, and pet care businesses.
At‑Home PCR Diagnostics for Pets
The company’s flagship product, the Petwealth Pack, includes fecal, oral, and respiratory PCR panels designed to screen for more than 100 health markers in dogs and cats. The kit is intended to allow pet owners to collect samples at home and receive results within 24 to 48 hours.
According to the company, the platform is designed to translate complex diagnostic data into simplified health insights using AI‑based analysis tools.
Industry Partnerships
Petwealth announced two strategic partnerships as part of its launch.
The company will serve as the exclusive diagnostic partner for Kennel Connection, a pet care management software platform used by more than 5,500 facilities across the United States. The partnership is expected to integrate PCR screening into the daily operations of pet care providers such as boarding facilities, daycares, and grooming businesses.
Petwealth has also partnered with telehealth platform Pawp to connect pet owners with licensed veterinarians who can help interpret diagnostic results and provide guidance on next steps.
Company Background
Petwealth was founded in 2025 by Angelo Palivos and Zoë Barry. The company focuses on proactive pet health monitoring using molecular diagnostics and AI‑driven analytics.
The platform is designed to provide earlier insights into potential health concerns by analyzing biological markers before clinical symptoms appear.
Information sourced from the company’s press release.
